MedTrace Logo

Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer

NCT05372692 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2023-07-17

No results posted yet for this study

Summary

Early-stage Clinical Study of mesothelin-specific Chimericantigen Receptor T Cells (LD013) in Subjects With Refractory or Relapsed mesothelin-positive Ovarian Cancer

Conditions

Interventions

DRUG

mesothelin-specific chimeric antigen receptor T cell injection

Autologous T cell injection

Sponsors & Collaborators

  • Nanjing Blue Shield Biotech Co.,Ltd

    collaborator UNKNOWN

  • Weijia Fang, MD

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-12
Primary Completion
2023-02-01
Completion
2023-02-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05372692 on ClinicalTrials.gov